These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1026 related items for PubMed ID: 30246298

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H, Yu C, Jiang J, Huang C, Yao X, Xu Q, Yu F, Lou L, Fang J.
    Cancer Biol Ther; 2016 Apr 02; 17(4):346-54. PubMed ID: 26853765
    [Abstract] [Full Text] [Related]

  • 6. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J.
    Int J Mol Sci; 2017 Feb 14; 18(2):. PubMed ID: 28216573
    [Abstract] [Full Text] [Related]

  • 7. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G, Li L, Qiu Y, Sun W, Ren T, Lv Y, Liu M, Wang X, Tao H, Zhao L, Cao J, He L, Li H, Gu H.
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec 08; 53(12):1625-1639. PubMed ID: 34586349
    [Abstract] [Full Text] [Related]

  • 8. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ, Song D, Kim J, Kim JY, Eom J, Sung B, Son YG, Kim YM, Lee SH, You WK, Jung J.
    MAbs; 2021 Dec 08; 13(1):1914885. PubMed ID: 33904380
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J, Dong L, Wang L, Wang L, Zhang J, Chen F, Zhang X, Huang M, Li S, Ma W, Xu Q, Huang C, Fang J, Wang C.
    Eur J Pharm Sci; 2016 Oct 10; 93():274-86. PubMed ID: 27509865
    [Abstract] [Full Text] [Related]

  • 11. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY, Hsu HJ, Wu CY, Chen HS, Chou YC, Tsou YL, Peng HP, Jian JW, Yu CM, Chiu YK, Chen IC, Tung CP, Hsiao M, Lin CL, Wang YA, Wang AH, Yang AS.
    MAbs; 2019 Jan 10; 11(1):153-165. PubMed ID: 30365359
    [Abstract] [Full Text] [Related]

  • 12. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, Polakis P, Flygare J, Polson AG.
    Clin Cancer Res; 2015 Jul 15; 21(14):3298-306. PubMed ID: 25840969
    [Abstract] [Full Text] [Related]

  • 13. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X, Jiang H, Bai W, Liu X, Miao Q, Wang L, Jin J, Cui A, Liu R, Li Z.
    Eur J Med Chem; 2021 Apr 15; 216():113297. PubMed ID: 33677351
    [Abstract] [Full Text] [Related]

  • 14. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, Venstrom K, Levashova Z, Sauer P, Migone TS, van der Horst EH, Halcomb RL, Jackson DY.
    Mol Pharm; 2015 Nov 02; 12(11):3986-98. PubMed ID: 26393951
    [Abstract] [Full Text] [Related]

  • 15. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF.
    Blood; 2003 Aug 15; 102(4):1458-65. PubMed ID: 12714494
    [Abstract] [Full Text] [Related]

  • 16. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
    Sijbrandi NJ, Merkul E, Muns JA, Waalboer DC, Adamzek K, Bolijn M, Montserrat V, Somsen GW, Haselberg R, Steverink PJ, Houthoff HJ, van Dongen GA.
    Cancer Res; 2017 Jan 15; 77(2):257-267. PubMed ID: 27872093
    [Abstract] [Full Text] [Related]

  • 17. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity.
    Shafiee S, Mirzaei R, Salehi M, Jalili N, Taheri A, Farahmand L.
    Iran J Immunol; 2023 Sep 01; 20(3):303-315. PubMed ID: 37434357
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
    Sharma S, Li Z, Bussing D, Shah DK.
    Drug Metab Dispos; 2020 May 01; 48(5):368-377. PubMed ID: 32086295
    [Abstract] [Full Text] [Related]

  • 19. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N, Allard-Vannier E, Martin C, Bryden F, Letast S, Colas C, Lakhrif Z, Collinet N, Dimier-Poisson I, Chourpa I, Viaud-Massuard MC, Joubert N.
    Bioconjug Chem; 2018 Nov 21; 29(11):3516-3521. PubMed ID: 30352511
    [Abstract] [Full Text] [Related]

  • 20. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
    Li ZH, Zhang Q, Wang HB, Zhang YN, Ding D, Pan LQ, Miao D, Xu S, Zhang C, Luo PH, Naranmandura H, Chen SQ.
    Invest New Drugs; 2014 Feb 21; 32(1):75-86. PubMed ID: 23903896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.